<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826575</url>
  </required_header>
  <id_info>
    <org_study_id>NU21-06-00086</org_study_id>
    <nct_id>NCT04826575</nct_id>
  </id_info>
  <brief_title>Pre-habilitation in Lung Surgery Candidates</brief_title>
  <official_title>High Intensity Respiratory Muscle Training as a Pre-habilitation in Lung Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anne's University Hospital Brno, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Palacky University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Anne's University Hospital Brno, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that high intensity respiratory muscle training will improve ventilatory&#xD;
      efficiency (VE/VCO2 slope) and will be associated with decreased PPC, decreased mortality and&#xD;
      better quality of life in lung resection candidates. Accordingly, the aim of this study will&#xD;
      be to compare rest and exercise ventilation and gas exchange parameters as well as&#xD;
      postoperative complications, quality of life and mortality in patients who undergo high&#xD;
      intensity respiratory muscle training compared to patients who receive the usual standard of&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung resection surgery is the major curative option for lung cancer. Therefore, it is&#xD;
      alarming that up to 37% of suitable patients are considered inoperable because of lung&#xD;
      function impairment and those suitable for operation still carry a significant risk of&#xD;
      especially postoperative pulmonary complications (PPC) development and increased mortality.&#xD;
      Several predictors of postoperative morbidity and mortality have been identified. However,&#xD;
      most of the factors are not easily modifiable before surgery. Ventilatory efficiency for&#xD;
      carbon dioxide (VE/VCO2 slope) is an exercise parameter that has been shown to predict&#xD;
      respiratory complications and mortality of lung resection candidates and to be superior to&#xD;
      peak oxygen uptake (peak VO2). Importantly, in contrast to most previously established PPC&#xD;
      risk factors, VE/VCO2 slope and peak VO2 may be therapeutically improved by physical and/or&#xD;
      respiratory muscle training (e.g. by prehabilitation) and may thereby enable preoperative&#xD;
      patient optimization. In thoracic surgery patients, trials looking at improvement of exercise&#xD;
      capacity and PPC development give conflicting results, probably because of huge heterogeneity&#xD;
      in terms of type, intensity and the length of pre-habilitation program. However, it seems&#xD;
      that inclusion of only selected patients that may benefit from pre-habilitation (high risk&#xD;
      patients), using VE/VCO2 slope and not peak VO2 to define the high risk patients and using&#xD;
      interventions that could effectively improve VE/VCO2 slope (like the inspiratory and&#xD;
      expiratory muscle training) is crucial and may be the key to lowering of postoperative&#xD;
      pulmonary complications. Therefore, we hypothesize that high intensity respiratory muscle&#xD;
      training will improve ventilatory efficiency (VE/VCO2 slope) and will be associated with&#xD;
      decreased PPC, decreased mortality and better quality of life in lung resection candidates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomized to control and intervention (pre-habilitation) group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
    <masking_description>Caretaking provider and investigators gathering data will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative pulmonary complications</measure>
    <time_frame>from the first 30 post-operative days or from the hospital stay</time_frame>
    <description>Post-operative pulmonary complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative cardiovascular complications</measure>
    <time_frame>from the first 30 post-operative days or from the hospital stay</time_frame>
    <description>Post-operative cardiovascular complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>from the first 30 post-operative days or from the hospital stay</time_frame>
    <description>duration of hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit length of stay</measure>
    <time_frame>from the first 30 post-operative days or from the hospital stay</time_frame>
    <description>duration of intensive care unit length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest drainage</measure>
    <time_frame>from the first 30 post-operative days or from the hospital stay</time_frame>
    <description>Duration of chest drainage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Post-Op Complication</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention will be done in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-Habilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of high intensity respiratory muscle training, optional smoking cessation and psychological support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High intensity inspiratory and expiratory muscle training</intervention_name>
    <description>Inspiratory Muscle Training will be performed using the Threshold inspiratory muscle trainer device (Threshold IMT®, Philips Respironics, Inc., Murrysville, PA, USA).&#xD;
Expiratory muscle training (EMT) will be performed using the Threshold positive expiratory pressure device (Threshold PEP®, Philips Respironics, Inc., Murrysville, PA, USA) or Expiratory Muscle Strength Trainer EMST 150TM (Aspire Products), depending on the initial MEP.&#xD;
Patients will train 2 times a day, 7 days per week, for 2 weeks.</description>
    <arm_group_label>Pre-Habilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ventilatory efficiency (VE/VCO2) ≥ 33&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication for lung resection (e.g. inoperable tumor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Cundrle, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Anne's University Hospital in Brno</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivan Cundrle, M.D., Ph.D.</last_name>
    <phone>00420543182553</phone>
    <email>Ivan.Cundrle@seznam.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Milos Chobola, M.D.</last_name>
    <phone>00420543182553</phone>
    <email>milos.chobola@fnusa.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian Brat, M.D., Ph.D.</last_name>
      <phone>00420532232193</phone>
      <email>Brat.Kristian@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Ladislav Mitas, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marek Plutinsky, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Filip Dosbaba, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Hartman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Kapustová, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anne's University Hospital</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivan Cundrle, M.D., Ph.D.</last_name>
      <phone>00420543182553</phone>
      <email>Ivan.Cundrle@seznam.cz</email>
    </contact>
    <contact_backup>
      <last_name>Milos Chobola, M.D.</last_name>
      <phone>00420543182553</phone>
      <email>milos.chobola@fnusa.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Andrej Mazur, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir Sramek, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavel Homolka, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zdenek Chovanec, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alena Sedlakova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palacky University Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77147</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milan Sova, M.D., Ph.D.</last_name>
      <phone>420588444648</phone>
      <email>milan.sova@upol.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Jakubec, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Genzor, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marek Szkorupa, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eliska Sovova, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marketa Sovova, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbora Imrichová</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monika Mikulaskova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Sanchez-Lorente D, Navarro-Ripoll R, Guzman R, Moises J, Gimeno E, Boada M, Molins L. Prehabilitation in thoracic surgery. J Thorac Dis. 2018 Aug;10(Suppl 22):S2593-S2600. doi: 10.21037/jtd.2018.08.18. Review.</citation>
    <PMID>30345096</PMID>
  </reference>
  <reference>
    <citation>Baser S, Shannon VR, Eapen GA, Jimenez CA, Onn A, Keus L, Lin E, Morice RC. Pulmonary dysfunction as a major cause of inoperability among patients with non-small-cell lung cancer. Clin Lung Cancer. 2006 Mar;7(5):344-9.</citation>
    <PMID>16640807</PMID>
  </reference>
  <reference>
    <citation>Agostini P, Cieslik H, Rathinam S, Bishay E, Kalkat MS, Rajesh PB, Steyn RS, Singh S, Naidu B. Postoperative pulmonary complications following thoracic surgery: are there any modifiable risk factors? Thorax. 2010 Sep;65(9):815-8. doi: 10.1136/thx.2009.123083.</citation>
    <PMID>20805178</PMID>
  </reference>
  <reference>
    <citation>Brunelli A, Varela G, Refai M, Jimenez MF, Pompili C, Sabbatini A, Aranda JL. A scoring system to predict the risk of prolonged air leak after lobectomy. Ann Thorac Surg. 2010 Jul;90(1):204-9. doi: 10.1016/j.athoracsur.2010.02.054.</citation>
    <PMID>20609776</PMID>
  </reference>
  <reference>
    <citation>Stanzani F, Paisani Dde M, Oliveira Ad, Souza RC, Perfeito JA, Faresin SM. Morbidity, mortality, and categorization of the risk of perioperative complications in lung cancer patients. J Bras Pneumol. 2014 Jan-Feb;40(1):21-9. doi: 10.1590/S1806-37132014000100004. English, Portuguese.</citation>
    <PMID>24626266</PMID>
  </reference>
  <reference>
    <citation>Brunelli A, Belardinelli R, Pompili C, Xiumé F, Refai M, Salati M, Sabbatini A. Minute ventilation-to-carbon dioxide output (VE/VCO2) slope is the strongest predictor of respiratory complications and death after pulmonary resection. Ann Thorac Surg. 2012 Jun;93(6):1802-6. doi: 10.1016/j.athoracsur.2012.03.022. Epub 2012 May 4.</citation>
    <PMID>22560968</PMID>
  </reference>
  <reference>
    <citation>Torchio R, Guglielmo M, Giardino R, Ardissone F, Ciacco C, Gulotta C, Veljkovic A, Bugiani M. Exercise ventilatory inefficiency and mortality in patients with chronic obstructive pulmonary disease undergoing surgery for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2010 Jul;38(1):14-9. doi: 10.1016/j.ejcts.2010.01.032. Epub 2010 Mar 30.</citation>
    <PMID>20356758</PMID>
  </reference>
  <reference>
    <citation>Fu TC, Wang CH, Lin PS, Hsu CC, Cherng WJ, Huang SC, Liu MH, Chiang CL, Wang JS. Aerobic interval training improves oxygen uptake efficiency by enhancing cerebral and muscular hemodynamics in patients with heart failure. Int J Cardiol. 2013 Jul 15;167(1):41-50. doi: 10.1016/j.ijcard.2011.11.086. Epub 2011 Dec 22.</citation>
    <PMID>22197120</PMID>
  </reference>
  <reference>
    <citation>Tucker WJ, Lijauco CC, Hearon CM Jr, Angadi SS, Nelson MD, Sarma S, Nanayakkara S, La Gerche A, Haykowsky MJ. Mechanisms of the Improvement in Peak VO(2) With Exercise Training in Heart Failure With Reduced or Preserved Ejection Fraction. Heart Lung Circ. 2018 Jan;27(1):9-21. doi: 10.1016/j.hlc.2017.07.002. Epub 2017 Aug 4. Review.</citation>
    <PMID>28870770</PMID>
  </reference>
  <reference>
    <citation>Kasahara Y, Izawa KP, Watanabe S, Osada N, Omiya K. The Relation of Respiratory Muscle Strength to Disease Severity and Abnormal Ventilation During Exercise in Chronic Heart Failure Patients. Res Cardiovasc Med. 2015 Sep 15;4(4):e28944. doi: 10.5812/cardiovascmed.28944. eCollection 2015 Nov.</citation>
    <PMID>26528451</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Anne's University Hospital Brno, Czech Republic</investigator_affiliation>
    <investigator_full_name>Ivan Cundrle</investigator_full_name>
    <investigator_title>Ivan Cundrle M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>cardiopulmonary exercise testing</keyword>
  <keyword>VE/VCO2</keyword>
  <keyword>PETCO2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

